The data are from a randomized, double-blind study of acquired immune deficiency syndrome (AIDS) patients with advanced immune suppression (cluster of differentiation 4 (CD4) cells count of less than or equal to 50 cells/mm3) (Henry et al., 1998; Fitzmaurice et al., 2011). Patients in the AIDS Clinical Trial Group Study 193A were randomized to dual or triple combinations of human immunodeficiency virus-1 reverse transcriptase inhibitors. Specifically, patients were randomized to one of four daily regimens.
A data frame with 4708 observations on the following 7 variables:
idpatient identifier; in total there are 1177 patients.
weekcnominal visit variable (weeks 8, 16, 24, 32).
treatmentallocated treatment regimens; 1 = zidovudine alternating monthly with 400mg didanosine, 2 = zidovudine plus 2.25mg of zalcitabine, 3 = zidovudine plus 400mg of didanosine, and 4 = zidovudine plus 400mg of didanosine plus 400mg of nevirapine.
agepatients' age (years).
sexpatients' sex (1 = male, 0 = female)
cd4.blbaseline value of CD4 cells count + 1.
cd4CD4 cells count + 1.
Henry, K., Erice, A., Tierney, C., Balfour, H.H. Jr., Fischl, M.A., Kmack, A., Liou, S.H., Kenton, A., Hirsch, M.S., Phair, J., Martinez, A., Kahn, J.O., for the AIDS Clinical Trial Group 193A Study Team. (1998). A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 19, 339-349, tools:::Rd_expr_doi("10.1097/00042560-199812010-00004").
Fitzmaurice, G.M., Laird, N.M., and Ware, J.H. (2011). Applied Longitudinal Analysis 2nd ed., Wiley, New York, tools:::Rd_expr_doi("10.1002/9781119513469").